Skip Navigation

A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 IDH1-mutant glioma

Brief Summary

Type:
Brain Tumors / Neurologic Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05303519

Study #:
STUDY00161706

Start Date:
Oct 28, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05303519

View Complete Trial Details & Eligibility at ClinicalTrials.gov